Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748971 | 0.93 | KDM4E (0.60) | CYP19A1HTR1AADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL15487723 | 0.92 | KDM4E (0.63) | CYP19A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5659691 | 0.90 | MAOB (0.58) | CYP19A1MAPK1HTR1AGAAMAPT | |
| SCHEMBL5503430 | 0.89 | SMPD1 (0.50) | SMPD1HDAC1HDAC8HDAC6CYP19A1 | |
| Hydrochloric Acid SCHEMBL11596441 | 0.88 | GAA (0.56) | CYP19A1MAPK1KDM4EGAAMAPT | |
| SCHEMBL7007168 | 0.86 | HTR1A (0.47) | SMPD1HDAC1HDAC8HDAC6CYP19A1 | |
| SCHEMBL15814937 | 0.84 | CYP19A1 (0.50) | SMPD1HDAC1HDAC8HDAC6CYP19A1 | |
| SCHEMBL5704614 | 0.84 | SIGMAR1 (0.59) | RAB9A | |
| SCHEMBL1157301 | 0.83 | PDE4A (0.56) | CYP19A1 | |
| SCHEMBL2742565 | 0.83 | KDM4E (0.68) | MAPK1HSD17B10KDM4ESMN1; SMN2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111732584-B | Diaryl substituted fused heterocycle compound and preparation method and application thereof in pharmacy | 复旦大学 | 2024-02-27 | — | — | CN | disclosed |
| US-20230115176-A1 | Complement Modulators and Related Methods | RA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-3947352-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020205501-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| CN-111732584-A | Diaryl substituted fused heterocyclic compound, preparation method thereof and application thereof in pharmacy | 复旦大学 | 2020-10-02 | — | — | CN | disclosed |
| CN-106536509-B | Novel compounds as dual inhibitors of histone methyltransferase and DNA methyltransferase | 基础应用医学研究基金会 | 2020-06-09 | — | — | CN | disclosed |
| EP-3154957-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACION PARA LA INVESTIG MEDICA APLICADA (ES) | 2019-11-20 | — | — | EP | disclosed |
| US-20190127354-A1 | 2,4,6,7-TETRASUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2019-05-02 | — | — | US | disclosed |
| EP-3421038-A1 | NAPHTHYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Nanjing Natinefy Pharmatech Co., Ltd. (CN) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018229139-A1 | NOVEL COMPOUNDS FOR USE IN CANCER | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-12-20 | — | — | WO | disclosed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005113489-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1465630-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| US-4169093-A | 2-Amino-5-phenylmethoxy-6-methoxybenzothiazole hydrochloride | MORTON-NORWICH PRODUCTS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115176-A1 | Complement Modulators and Related Methods | C5, C9, C1QBP | SMPD1 300/4885HDAC1 2943/4885HDAC8 3160/4885 |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | SMPD1 4882/4885HDAC1 1045/4885HDAC8 1370/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | SMPD1 477/4885HDAC1 2950/4885HDAC8 2373/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | SMPD1 2393/4885HDAC1 375/4885HDAC8 724/4885 |
| US-20190127354-A1 | 2,4,6,7-TETRASUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | DNMT3B, DNMT1, DNMT3A | SMPD1 3826/4885HDAC1 73/4885HDAC8 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.